Skip to main content

A Superdevice for Depression and Anxiety

Fisher Wallace Labs is on a mission to vastly increase access to mental healthcare. We develop and commercialize wearable brain stimulation technology for the treatment of depression, anxiety, and other neuropsychiatric and cognitive disorders.

Sign Up

Clinically Proven

Our technology was recently proven to be rapidly effective in two large clinical trials for the treatment of Major Depressive Disorder and Generalized Anxiety Disorder, the latter of which was conducted in collaboration with the Seattle Police Department and Washington State University. Previous research includes a successful pilot study conducted at Beth Israel Hospital for the treatment of Bipolar II Depression, and a substance use rehabilitation study conducted at Phoenix House. 

Sign Up

Our $40M Proof-of-Concept

Under temporary FDA clearance, we distributed 100,000 Version 1.0 devices through 14,000 prescribers, generating $40 million in revenue, and obtained Medicaid reimbursement in Maine (MaineCare). We are currently engaged in obtaining regulatory approval for OAK, our Version 2.0 technology that was designed in collaboration with the teams behind Beats and Nest, with the goal of commercialization in 2025 and ultimately achieving smartphone scale. 

Sign Up


Kelly Roman


Kelly has helped pioneer the wearable brain stimulation category since 2009, with a focus on innovative product development and clinical research. The results of the company's most recent trial will be published in The Journal of Clinical Psychiatry and validate its Version 2.0 wearable, OAK, as one of the most rapid treatments for depression.

Kelly led OAK's industrial design and engineering in collaboration with the teams behind Beats, Nest and the Microsoft HoloLens. Most recently, Kelly partnered with Dr. Maurizio Fava, Psychiatrist-in-Chief of Massachusetts General Hospital, to design and conduct a pivotal depression trial in support of FDA approval.

Directors & Advisors

Chip Fisher


After graduating from Harvard and serving as a sales executive at IBM, Chip acquired the original intellectual property to the Fisher Wallace Stimulator and is the company’s CFO and largest shareholder - and a recent TEDx contributor.

Simon Webster


Simon is CEO of Vistra and founder of SHUFL Capital, a seed investing platform. He previously led CPA Global (IP software and services) as CEO through its merger with Clarivate.

Maurizio Fava, MD


Dr. Fava is Psychiatrist-In-Chief, Department of Psychiatry, at Massachusetts General Hospital, and Director, Division of Clinical Research, at Mass General Research Institute.

David Shulkin, MD


Dr. Shulkin is a former US Secretary of Veterans Affairs and a former CEO of Beth Israel Medical Center.

Michael Greenberg, MD, MPH, FACEP


Mike is an emeritus professor of emergency medicine at Drexel University College of Medicine and a professor of public health in Drexel's Dornsife School of Public Health.

Scott Witt


Scott is a Brand and Creative executive operator who previously served as Creative Director at Apple, advisor to Peloton and Chief Brand Officer at Twill.

Neil Liebowitz, MD, JD


Neil recently served as Chief Medical Officer for two game-changing mental healthcare companies: Talkspace and Beacon Health Options.

Join Us

We are a patient-owned healthcare company

Back to top